{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-016474","form_type":"8-K","ticker":"CERO","cik":"0001870404","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2026-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.623641+00:00","generated_at":"2026-05-16T02:50:07.089235+00:00","sec_items":["1.01","2.03","3.02","4.01","5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"CERo Therapeutics issues $937.5k convertible note, dismisses auditor Wolf & Co., appoints Eric Francois to board","bullets":["Issued $937,500 convertible note to Keystone Capital Partners at $750,000; 10% interest, matures July 2027, convertible at discount to market.","Dismissed Wolf & Company, P.C. as auditor effective Feb 13, 2026; no disagreements, but prior material weakness in internal controls noted.","Appointed Salberg & Company, P.A. as new auditor effective Feb 13, 2026.","Appointed Eric Francois to board, increasing size to 7; he served as Managing Director at Raymond James, CFO at Scynexis."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-016474","json":"https://secwatch.observer/filing/0001213900-26-016474.json","markdown":"https://secwatch.observer/filing/0001213900-26-016474.md","text":"https://secwatch.observer/filing/0001213900-26-016474.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026016474/0001213900-26-016474-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026016474/ea0276984-8k_ceroa.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T02:50:07.089235+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"85b7fbee698b1ef13e0059de746abeacd36cb503","claim":"CERO THERAPEUTICS HOLDINGS, INC. dismissed Wolf & Company, P.C. as its auditor.","evidence_excerpt":"The Company’s audit committee of the board of directors (the “Audit Committee”) approved the decision to dismiss Wolf & Company, P.C. (“Wolf”), as the Company’s independent registered public accounting firm, effective as of February 13, 2026.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026016474/0001213900-26-016474-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"dismissal"},{"label":"Auditor","value":"Wolf & Company, P.C."},{"label":"Successor","value":"Salberg & Company, P.A."}],"fact_type":"auditor_change"},{"claim_id":"fcf6967ef91680d9dded67eadeba28e14fbe892d","claim":"CERO THERAPEUTICS HOLDINGS, INC. engaged Salberg & Company, P.A. as its auditor.","evidence_excerpt":"The Company’s audit committee of the board of directors (the “Audit Committee”) approved the appointment of Salberg & Company, P.A. (“Salberg”) as the Company’s independent registered public accounting firm, effective following the finalization of the terms of an engagement letter therewith and execution thereof of February 11, 2026, with such appointment effective as of February 13, 2026.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026016474/0001213900-26-016474-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"engagement"},{"label":"Auditor","value":"Salberg & Company, P.A."}],"fact_type":"auditor_change"},{"claim_id":"7a34263d5640eb41c9ca784b00694b3152f56b99","claim":"CERO THERAPEUTICS HOLDINGS, INC. incurred convertible notes of $750,000 with Keystone Capital Partners, LLC at 10% per annum maturing July 9, 2027.","evidence_excerpt":"On February 9, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for a purchase price of $750,000, having a principal face value of $937,500 (the “Note”) to Keystone Capital Partners, LLC (“Lender”).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026016474/0001213900-26-016474-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$750,000"},{"label":"Counterparty","value":"Keystone Capital Partners, LLC"},{"label":"Rate","value":"10% per annum"},{"label":"Maturity","value":"July 9, 2027"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"d948b32a0316b60582a0f644b908bf1b799cd3b5","claim":"CERO THERAPEUTICS HOLDINGS, INC. issued convertible note to Keystone Capital Partners, LLC for $750,000.","evidence_excerpt":"On February 9, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for a purchase price of $750,000, having a principal face value of $937,500 (the “Note”) to Keystone Capital Partners, LLC (“Lender”).","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026016474/0001213900-26-016474-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"convertible note"},{"label":"Purchaser","value":"Keystone Capital Partners, LLC"},{"label":"Consideration","value":"$750,000"}],"fact_type":"equity_issuance"},{"claim_id":"5599ea82aae7728cb06be2fd8e9c3822d722c54f","claim":"CERO THERAPEUTICS HOLDINGS, INC. entered into Note with Keystone Capital Partners, LLC valued at $750,000 (effective 2026-02-09).","evidence_excerpt":"On February 9, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for a purchase price of $750,000, having a principal face value of $937,500 (the “Note”) to Keystone Capital Partners, LLC (“Lender”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026016474/0001213900-26-016474-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"Keystone Capital Partners, LLC"},{"label":"Value","value":"$750,000"},{"label":"Effective","value":"2026-02-09"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}